John Reader

Construction Project Manager @Statera Energy

As a sterile subcutaneous injectable is manufactured under highly specialised conditions, following a complex, multistage formulation process. This requires a range of high-specification equipment in a controlled operating environment to ensure aseptic production. The continued global demand for particularly in Japan and emerging markets including China and Russia, has resulted in the decision to invest in replacing some of the existing facilities where the medicine is currently produced at the Macclesfield site.